PTGS2 and obesity disorder: These results thus advocate that pazopanib’s anti-inflammatory effect on 3T3-L1 preadipocytes and differentiated 3T3-L1 cells by down-regulating COX-2 may further contribute to the drug’s anti-obesity effect.